MCID: DBT004
MIFTS: 45

Diabetic Polyneuropathy malady

Categories: Endocrine diseases, Neuronal diseases

Aliases & Classifications for Diabetic Polyneuropathy

About this section

Aliases & Descriptions for Diabetic Polyneuropathy:

Name: Diabetic Polyneuropathy 10 47 12
Diabetes Mellitus with Polyneuropathy 10
 
Polyneuropathy in Diabetes 10
Diabetic Polyneuropathies 65

Classifications:



External Ids:

Disease Ontology10 DOID:12785
ICD9CM29 357.2
MeSH36 D003929
UMLS65 C0271680

Summaries for Diabetic Polyneuropathy

About this section
MalaCards based summary: Diabetic Polyneuropathy, also known as diabetes mellitus with polyneuropathy, is related to mast syndrome and baritosis. An important gene associated with Diabetic Polyneuropathy is AKR1B1 (Aldo-Keto Reductase Family 1, Member B1 (Aldose Reductase)), and among its related pathways are Notch-mediated HES/HEY network and Detoxification of Reactive Oxygen Species. Affiliated tissues include spinal cord, liver and breast, and related mouse phenotypes are vision/eye and no phenotypic analysis.

Related Diseases for Diabetic Polyneuropathy

About this section

Graphical network of the top 20 diseases related to Diabetic Polyneuropathy:



Diseases related to diabetic polyneuropathy

Symptoms for Diabetic Polyneuropathy

About this section

Drugs & Therapeutics for Diabetic Polyneuropathy

About this section

Drugs for Diabetic Polyneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 114)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DopamineapprovedPhase 4, Phase 2308462-31-7, 51-61-6681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine Hcl
Dopamine Hydrochloride
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
 
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
2
NorepinephrineapprovedPhase 4, Phase 259551-41-2439260
Synonyms:
(-)-(R)-Norepinephrine
(-)-Arterenol
(-)-Arterenol free base
(-)-NORADRENALINE
(-)-Noradrenaline
(-)-Norepinephrine
(-)-alpha-(Aminomethyl)protocatechuyl alcohol
(R)-(-)-Norepinephrine
(R)-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol
(R)-4-(2-amino-1-Hydroxyethyl)-1,2-benzenediol
(R)-Noradrenaline
(R)-Norepinephrine
1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9CI)
4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol
4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol
4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol
4899-05-2
51-40-1 (l-tartrate (1:1))
51-41-2
66197-73-7
A7257_SIGMA
AC1L96ZT
ALBB-006229
Adrenor
Aktamin
Arterenol
BRN 4231961
BSPBio_002079
C00547
CHEBI:18357
CHEMBL1437
CID439260
D-(-)-Noradrenaline
D00076
D53D5E3A-2360-4CA9-8031-6C2CD4062FD5
DB00368
DivK1c_000230
EINECS 200-096-6
HMS1920B08
HMS2089E18
HMS2091J08
HMS500L12
IDI1_000230
KBio1_000230
KBio2_001489
KBio2_004057
KBio2_006625
KBio3_001579
KBioGR_000635
KBioSS_001489
L-2-Amino-1-(3,4-dihydroxyphenyl)ethanol
L-3,4-Dihydroxyphenylethanolamine
L-3,4-dihydroxyphenylethanolamine
L-Arterenol
L-Noradrenaline
L-Norepinephrine
L-alpha-(Aminomethyl)-3,4-dihydroxybenzyl alcohol
L-alpha-(aminomethyl)-3,4-dihydroxybenzyl alcohol
L-arterenol
L-noradrenaline
LS-42676
 
LT03330026
LT4
Levarterenol
Levarterenolo
Levarterenolo [DCIT]
Levoarterenol
Levonor
Levonoradrenaline
Levonorepinephrine
Levophed
NCGC00159406-02
NCGC00159406-03
NCGC00159406-04
NCGC00159406-05
NCGC00159406-06
NCGC00159406-07
NCGC00159406-09
NINDS_000230
Nor adrenalin
Nor adrenalin (TN)
Nor-Epirenan
Noradrenalin
Noradrenalina
Noradrenalina [Italian]
Noradrenaline
Noradrenaline (JP15)
Noradrenalinum
Norartrinal
Noreinefrina
Noreinefrina [INN-Spanish]
Norepinefrina
Norepinephrine
Norepinephrine (INN)
Norepinephrine Noradrenalin
Norepinephrine [INN:JAN]
Norepinephrine l-Tartrate (1:1)
Norepinephrinum
Norepinephrinum [INN-Latin]
Norepirenamine
PDSP1_001111
PDSP2_001095
SGCUT00123
SPBio_001048
SPECTRUM1500436
STK503776
Spectrum2_001064
Spectrum3_000520
Spectrum4_000078
Spectrum5_001068
Spectrum_001009
Sympathin E
UNII-X4W3ENH1CV
bmse000404
l-1-(3,4-Dihydroxyphenyl)-2-aminoethanol
l-2-Amino-1-(3,4-dihydroxyphenyl)ethanol
nchembio.284-comp2
nchembio.64-comp2
nchembio705-1
noradrenaline
norepinefrina
norepinephrine
norepinephrinum
to_000024
3
CilostazolapprovedPhase 410073963-72-12754
Synonyms:
3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone
3,4-dihydro-6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxyl)-3,4-dihydrocarobostyril
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone
6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one
6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
73963-72-1
89332-50-3
AC-4334
AC1L1EE2
BRD-K67017579-001-04-2
BRD-K67017579-001-05-9
BRD-K67017579-001-07-5
BRD-K67017579-001-13-3
BRN 3632107
BSPBio_002759
C 0737
C045645
C0737_SIGMA
C20H27N5O2
CHEBI:31401
CHEMBL799
CID2754
CL23867
CPD000058428
Cilostazol
Cilostazol (JP15/USAN/INN)
Cilostazol [INN:JAN]
Cilostazole
Cilostazolum
Cilostazolum [INN-Latin]
D01896
DB01166
EU-0100218
HMS1922N15
HMS2093M14
KBio3_002259
KBioGR_001184
 
LS-142693
Lopac-C-0737
Lopac0_000218
MLS000028470
MLS000758281
MLS000759507
MLS001076067
MLS002153891
MolPort-001-758-007
NCGC00015207-01
NCGC00015207-02
NCGC00015207-06
NCGC00015207-10
NCGC00022153-02
NCGC00022153-04
NCGC00022153-05
NCGC00022153-06
NCGC00022153-07
OPC 13013
OPC 21
OPC-13013
OPC-21
Otsuka brand of cilostazol
Pletaal
Pletal
Pletal (TN)
Pletal, Cilostazol
S1294_Selleck
SAM001246734
SAM001247085
SMR000058428
SPBio_001256
SPECTRUM1505230
Spectrum2_001118
Spectrum3_001170
Spectrum4_000772
Spectrum5_001762
TL8005113
Tocris-1692
UNII-N7Z035406B
ZINC01552174
cilostazol
4
LidocaineapprovedPhase 4, Phase 21103137-58-63676
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
AKOS001026768
ARONIS23855
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
Afterburn
Akten
Alphacaine
Anestacon
Anestacon Jelly
BIDD:GT0342
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
Bikini Zone Medicated
Bikini Zone Medicated Creme
Bio-0767
Bio-scriptives Lidum
Bio-scriptives Lidum Hemorroidal (anorectal)
Bio-scriptives Lidum Topical Analgesic
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
Burn Relief Leader
C07073
C14H22N2O
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
CPD000058189
Cappicaine
Cito optadren
Comfortcaine
Cuivasil
Curacaine Transdermal Corporation
D00358
DB00281
Dalcaine
Dentipatch
Dentipatch (TN)
Derma Numb
DermaFlex
Desert Harvest Releveum
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Dr. Numb
Dr. Richs Numbing
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla
Emla Cream
Esracaine
FT-0082378
Gigi Anesthetic Numbing
Gravocain
H-releve Hemorrhoidal
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
Hawaiian Tropic
Hush Anesthetic
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L-Caine
L0156
L1026_SIGMA
L7757_SIGMA
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
LIDOPEN
LQZ
LS-805
Lanabiotic
 
Laryng-o-jet
Leostesin
Lida-Mantle
Lidall
Lidocaina
Lidocaina [INN-Spanish]
Lidocaine
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine 4% Cream
Lidocaine Carbonate
Lidocaine Hydrocarbonate
Lidocaine Hydrochloride
Lidocaine Monohydrochloride
Lidocaine [USAN:INN:JAN]
Lidocaine hydrochloride
Lidocainum
Lidocainum [INN-Latin]
Lidocare Mist
Lidocaton
Lidocream 4
Lidocream 5
Lidoderm
Lidoderm 5
Lidoject-1
Lidoject-2
Lifestyles Epic Male Genital Desensitizer
Lignocaine
Lignocainum
Lingocaine
Lmx4
Lmx5
Lopac-L-5647
Lopac0_000669
MLS000069724
MLS000758263
MLS001074177
Maricaine
Maybridge1_002571
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
NINDS_000174
NSC 40030
NSC40030
Norwood Sunburn Spray
Numb Master Topical Anesthetic
Numb Nuts
Ocean Potion Instant Burn Relief Ice
Octocaine
Octocaine-100
Octocaine-50
Plum Smooth Plumb Numb Gelee
Premjact Male Desensitizer Pound International
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Recticare
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
SPBio_001525
SPBio_002100
STK552033
Simplicity Desensitizing
Simply Numb Endure
Solarcaine
Solarcaine aloe extra burn relief cream
Solcain
Sole Serum
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
Spectrum_001118
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Walgreens Aloe Vera Pain Relieving
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocaine-mpf
Xylocard
Xylocitin
Xyloneural (free base)
Xylotox
Zcaine Fast Acting Anesthetic
Zilactin-L
Zingo
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
alpha-Diethylamino-2,6-dimethylacetanilide
alpha-diethylamino-2,6-dimethylacetanilide
lidocaine
nchembio.65-comp16
α-diethylamino-2,6-dimethylacetanilide
5
Pregabalinapproved, illicit, investigationalPhase 4, Phase 2, Phase 1340148553-50-85486971
Synonyms:
(3S)-3-(aminomethyl)-5-methylhexanoic acid
(R-)-3-isobutyl GABA
(S)-3-(Aminomethyl)-5-methylhexanoic acid
(S)-3-Isobutyl gaba
(S+)-3-isobutyl GABA
121GE001
148553-50-8
3-Isobutyl gaba
3-isobutyl GABA
AC-1158
AC1NUP03
AKOS005145504
C080245
C8H17NO2
CHEBI:236161
CHEMBL1059
CI 1008
CI-1008
CID5486971
 
D02716
DB00230
FT-0080911
HSDB 7530
LS-75191
Lyrica
Lyrica (TN)
MolPort-000-861-733
PD 144723
PD-144723
Pregabalin
Pregabalin (JAN/USAN/INN)
Pregabalin [USAN]
Pregablin
S-(+)-3-isobutylgaba
S1731_Selleck
SBB062901
TL8001062
TOS-BB-0910
UNII-55JG375S6M
6
Folic Acidapproved, nutraceuticalPhase 4, Phase 3292459-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic Acid
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
 
Folsaeure
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
7
AcetylcholineexperimentalPhase 4, Phase 068951-84-3187
Synonyms:
ACh
Acetyl choline ion
Acetylcholine Chloride
Acetylcholine cation
 
Acetylcholinium: acetyl-Choline
Choline acetate
Choline acetate (ester)
Miochol E
O-Acetylcholine
acetylcholine chloride
8NarcoticsPhase 4, Phase 3, Phase 22709
9AnticonvulsantsPhase 4, Phase 3, Phase 2, Phase 12249
10MicronutrientsPhase 4, Phase 33901
11Thioctic AcidPhase 4, Phase 3, Phase 2104
12calcium channel blockersPhase 4, Phase 3, Phase 2, Phase 11743
13AntioxidantsPhase 4, Phase 32442
14Calcium, DietaryPhase 4, Phase 3, Phase 2, Phase 14678
15Serotonin and Noradrenaline Reuptake InhibitorsPhase 4, Phase 2391
16Anti-Asthmatic AgentsPhase 42796
17Trace ElementsPhase 4, Phase 33900
18Vitamin B ComplexPhase 4, Phase 32847
19Anti-Arrhythmia AgentsPhase 4, Phase 22371
20Central Nervous System DepressantsPhase 4, Phase 3, Phase 2, Phase 110016
21Diuretics, Potassium SparingPhase 4, Phase 21445
22Anti-Anxiety AgentsPhase 4, Phase 3, Phase 2, Phase 11529
23Anesthetics, LocalPhase 4, Phase 22347
24
SerotoninPhase 4, Phase 2314750-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
25Analgesics, OpioidPhase 4, Phase 3, Phase 22304
26VitaminsPhase 4, Phase 33857
27AnestheticsPhase 4, Phase 27385
28Sodium Channel BlockersPhase 4, Phase 21180
29Neurotransmitter Uptake InhibitorsPhase 4, Phase 22857
30Protective AgentsPhase 4, Phase 3, Phase 25651
31Platelet Aggregation InhibitorsPhase 41935
32Respiratory System AgentsPhase 43931
33Vasodilator AgentsPhase 42926
34AbobotulinumtoxinAPhase 4, Phase 0588
35Phosphodiesterase InhibitorsPhase 41062
36Phosphodiesterase 3 InhibitorsPhase 4113
37Bronchodilator AgentsPhase 42377
38Fibrinolytic AgentsPhase 41567
39Neuroprotective AgentsPhase 4, Phase 21376
40Peripheral Nervous System AgentsPhase 4, Phase 2, Phase 3, Phase 1, Phase 018510
41Botulinum ToxinsPhase 4, Phase 0616
42Botulinum Toxins, Type APhase 4, Phase 0588
43Antidepressive AgentsPhase 4, Phase 22367
44Dopamine AgentsPhase 4, Phase 23084
45Duloxetine HydrochloridePhase 4, Phase 2258
46Tranquilizing AgentsPhase 4, Phase 3, Phase 2, Phase 13597
47AnalgesicsPhase 4, Phase 3, Phase 2, Phase 19358
48OnabotulinumtoxinAPhase 4, Phase 0588
49Cholinergic AgentsPhase 4, Phase 03243
50IncobotulinumtoxinAPhase 4, Phase 0599

Interventional clinical trials:

(show top 50)    (show all 90)
idNameStatusNCT IDPhase
1Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the PhilippinesCompletedNCT01076478Phase 4
2Botulinum Toxin in Peripheral Neuropathic PainCompletedNCT01251211Phase 4
3Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive DisorderCompletedNCT00844194Phase 4
4Alpha Lipoic Acid for Treatment of Diabetic NeuropathyCompletedNCT02439879Phase 4
5Effect of Pulsing Electrical Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label StudyCompletedNCT00614341Phase 4
6Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic NeuropathyCompletedNCT00903851Phase 4
7Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic NeuropathyRecruitingNCT01770964Phase 4
8Efficacy, Safety, Tolerability and Pharmacokinetics of Concomitant Administration of Tramadol With Duloxetine or PregabalinWithdrawnNCT01116531Phase 4
9Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2)CompletedNCT00977483Phase 3
10Efficacy and Safety Study of Topical Capsaicin in Painful Diabetic NeuropathyCompletedNCT00993070Phase 2, Phase 3
11Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2)CompletedNCT00328601Phase 3
12Neuropathic Pain ManagementCompletedNCT01263132Phase 3
13Actovegin® Versus Placebo in Patients With Diabetic Polyneuropathy (AV-007-IM)CompletedNCT00483730Phase 3
14TempTouch IR Thermometry & Diabetic Patient Self-CareCompletedNCT00289497Phase 2, Phase 3
15A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral NeuropathyCompletedNCT00455520Phase 3
16Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor PolyneuropathyCompletedNCT00927914Phase 2, Phase 3
17Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor PolyneuropathyCompletedNCT00101426Phase 3
18An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid PolyneuropathyCompletedNCT00791492Phase 2, Phase 3
19Safety and Efficacy Study of Fx-1006A in Patients With Familial AmyloidosisCompletedNCT00409175Phase 2, Phase 3
20A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral NeuropathyCompletedNCT01041859Phase 3
21The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M TransthyretinCompletedNCT01435655Phase 3
22Efficacy and Safety of IONIS-TTR Rx in Familial Amyloid PolyneuropathyActive, not recruitingNCT01737398Phase 3
23Open-Label Extension Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)Enrolling by invitationNCT02175004Phase 3
24The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)Enrolling by invitationNCT02510261Phase 3
25Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD)Not yet recruitingNCT01868191Phase 3
26Efficacy and Safety Study of Thioctacid Oral Tablets 600mg to Treat Chinese Diabetic Patients With Distal Symmetric PolyneuropathyNot yet recruitingNCT01224353Phase 2, Phase 3
27A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)TerminatedNCT01063868Phase 3
28The Effect of Rosuvastatin in Diabetic Polyneuropathy: A Phase IIa Randomized Double-blind Placebo-controlled StudyCompletedNCT01622777Phase 2
29Pilot Study to Evaluate Magnetic Marker Imaging on Diabetic Polyneuropathy and GastroparesisCompletedNCT01607684Phase 2
30Statins for Oxidative Stress and Mitochondrial Function in Diabetic PolyneuropathyCompletedNCT02129231Phase 2
31Painful Diabetic Polyneuropathy Trial With a New Centrally Acting AnalgesicCompletedNCT00878293Phase 2
32Safety and Efficacy of MCC-257 in the Treatment of Diabetic PolyneuropathyCompletedNCT00307749Phase 2
33A Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic PoCompletedNCT00944697Phase 2
34Safety and Efficacy of GRT6005 in Pain Due to Diabetic PolyneuropathyCompletedNCT01347671Phase 2
35Safety and Efficacy Study in Subjects With Diabetic Neuropathic PainCompletedNCT00507936Phase 2
36Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509CompletedNCT00665145Phase 2
37Clinical Trial of SB-509 in Subjects With Diabetic NeuropathyCompletedNCT01079325Phase 2
38Clinical Trial of SB-509 in Subjects With Diabetic NeuropathyCompletedNCT00406458Phase 2
39Clinical Trial of SB-509 in Subjects With Diabetic NeuropathyCompletedNCT00476931Phase 2
40A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic PolyneuropathyCompletedNCT01201317Phase 2
41Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN).CompletedNCT00501202Phase 2
42Effect of C-Peptide on Diabetic Peripheral NeuropathyCompletedNCT00278980Phase 2
43Safety Study of Intranasal Insulin in Type 1 Diabetes and Diabetic Peripheral NeuropathyCompletedNCT01469559Phase 2
44A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic PainCompletedNCT01345045Phase 2
45Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral NeuropathyCompletedNCT00229437Phase 2
46Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral NeuropathyCompletedNCT00760955Phase 2
47A Study To Evaluate The Effect Of Topiramate On Clinical And Electrophysiological Parameters In Subjects With Diabetic Peripheral PolyneuropathyCompletedNCT00231673Phase 2
48Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic PainCompletedNCT00082316Phase 2
49The Effect of Ruboxistaurin on Small Fiber FunctionCompletedNCT00190970Phase 2
50A Trial to Investigate Safety and Efficacy of SPM927 in Painful Diabetic NeuropathyCompletedNCT00861445Phase 2

Search NIH Clinical Center for Diabetic Polyneuropathy

Genetic Tests for Diabetic Polyneuropathy

About this section

Anatomical Context for Diabetic Polyneuropathy

About this section

MalaCards organs/tissues related to Diabetic Polyneuropathy:

33
Spinal cord, Liver, Breast, Bone, Testes, Kidney, T cells

Animal Models for Diabetic Polyneuropathy or affiliated genes

About this section

MGI Mouse Phenotypes related to Diabetic Polyneuropathy:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053918.4AKR1B1, NGF, NOS1, NTF3, SOD2
2MP:00030128.2NGF, NOS1, PARP1, POLG, SOD3
3MP:00053697.5NGF, NOS1, NTF3, POLG, SLC25A4, SOD2
4MP:00053857.1C10orf2, NGF, NOS1, NTF3, POLG, SLC25A4
5MP:00053786.8AKR1B1, NGF, NOS1, NTF3, PARP1, POLG
6MP:00107686.6AKR1B1, C10orf2, NGF, NOS1, NTF3, PARP1
7MP:00053766.5AKR1B1, NGF, NOS1, NTF3, PARP1, POLG

Publications for Diabetic Polyneuropathy

About this section

Articles related to Diabetic Polyneuropathy:

(show top 50)    (show all 313)
idTitleAuthorsYear
1
Detrimental role of hyperuricemia on the cardio-reno-vascular system. (26414733)
2015
2
Aldo-keto reductase 1B15 (AKR1B15): a mitochondrial human aldo-keto reductase with activity towards steroids and 3-keto-acyl-coa conjugates. (25577493)
2015
3
Increasing trend in admissions for malignant hypertension and hypertensive encephalopathy in the United States. (25801877)
2015
4
Analysis of Nuclear Export Sequence Regions of FUS-Related RNA-Binding Proteins in Essential Tremor. (25375143)
2014
5
CD4 count as a predictor of adrenocortical insufficiency in persons with human immunodeficiency virus infection: How useful? (24381877)
2013
6
Visual outcome following extracapsular cataract extraction in mature cataracts with pseudoexfoliation syndrome: A retrospective study. (23772121)
2013
7
Validation of the MSKCC and Heng risk criteria models for predicting survival in patients with metastatic renal cell carcinoma treated with sunitinib. (24081805)
2013
8
Right bundle branch block: prevalence, risk factors, and outcome in the general population: results from the Copenhagen City Heart Study. (22947613)
2013
9
Elevated C-peptide and insulin predict increased risk of colorectal adenomas in normal mucosa. (22950808)
2012
10
Conjunctival lymphangiectasia: a report of 11 cases and review of literature. (22019374)
2012
11
Reliability and validity of ultrasonographic measurements of acromion-greater tuberosity distance in poststroke hemiplegia. (21530720)
2011
12
Ionizing radiation and kidney cancer among Japanese atomic bomb survivors. (20518663)
2010
13
Correlation of matrix metalloproteinases-2 and -9 with proinflammatory cytokines in Guillain-BarrAc syndrome. (20936699)
2010
14
IL-1beta-induced increase in intestinal epithelial tight junction permeability is mediated by MEKK-1 activation of canonical NF-kappaB pathway. (21048223)
2010
15
Adult final height after GH therapy for irradiation-induced GH deficiency in childhood survivors of brain tumors: the Belgian experience. (19969557)
2010
16
Surgical treatment of malignant peritoneal mesothelioma: past, present, and future. (19888634)
2010
17
Y-box binding protein-1 (YB-1) promotes cell cycle progression through CDC6-dependent pathway in human cancer cells. (20079629)
2010
18
Absolute quantification of potential cancer markers in clinical tissue homogenates using multiple reaction monitoring on a hybrid triple quadrupole/linear ion trap tandem mass spectrometer. (19323455)
2009
19
Association of the tag SNPs in the human SKT gene (KIAA1217) with lumbar disc herniation. (19338451)
2009
20
Effects of hyperhomocysteinemia on arterial pressure and nitric oxide production in pregnant rats. (19629051)
2009
21
Pharmacological profile of the new inotropic agent AT-11. (18031738)
2008
22
Comparison of the effect of individual saturated and unsaturated fatty acids on cell growth and death induction in the human pancreatic beta-cell line NES2Y. (18272185)
2008
23
Melioidosis and rainfall in Kuala Lumpur, Malaysia. (16965821)
2007
24
Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. (17065642)
2006
25
Association of inflammatory marker and highly sensitive C-reactive protein with aerobic exercise capacity, maximum oxygen uptake and insulin resistance in healthy middle-aged volunteers. (15791041)
2005
26
Muscle-eye-brain disease. Presentation of one case with genetic study]. (15954036)
2005
27
Molecular cloning of cDNAs and structural model analysis of two gonadotropin beta-subunits of snakehead fish (Channa maculata). (15922345)
2005
28
Lateral meningocele syndrome: vertical transmission and expansion of the phenotype. (15666314)
2005
29
A new model for dermatitis herpetiformis that uses HLA-DQ8 transgenic NOD mice. (15489956)
2004
30
The morphological characteristics and expression of cell cycle regulatory proteins in cellular variants of idiopathic focal segmental glomerulosclerosis. (15100731)
2004
31
An NF-kappaB-specific inhibitor, IkappaBalpha, binds to and inhibits cyclin-dependent kinase 4. (14621993)
2003
32
The metabotropic glutamate receptor 8 gene at 7q31: partial duplication and possible association with autism. (12676915)
2003
33
Delayed preconditioning of myocardium: current perspectives. (11518189)
2001
34
Penicilliosis-associated hemophagocytic syndrome in a human immunodeficiency virus-infected child: the first case report in children. (11460947)
2001
35
Lateralized P3 deficit in schizotypal personality disorder. (11032982)
2000
36
Role of interferon and interferon regulatory factors in early protection against Venezuelan equine encephalitis virus infection. (10208925)
1999
37
Genotoxicity of 3'-azido-3'-deoxythymidine in the human lymphoblastoid cell line, TK6: relationships between DNA incorporation, mutant frequency, and spectrum of deletion mutations in HPRT. (10526209)
1999
38
Identification of three novel mutations in human EYA1 protein associated with branchio-oto-renal syndrome. (9603436)
1998
39
Polyamine levels and ODC activity in intestinal-type and diffuse-type gastric carcinoma. (9073141)
1997
40
Diagnosis of macroglossia and indications for reduction glossectomy. (8760843)
1996
41
Bilateral spontaneous pneumothorax as the presenting feature in lymphangioleiomyomatosis. (7638376)
1995
42
Apoptosis regulatory gene NEDD2 maps to human chromosome segment 7q34-35, a region frequently affected in haematological neoplasms. (7789948)
1995
43
Radioimmunoassay versus flow cytometric assay to quantify LPS-binding protein (LBP) concentrations in human plasma. (7515085)
1994
44
From the Centers for Disease Control. Pneumonic plague--Arizona, 1992. (1404753)
1992
45
Distribution of mRNA of a Na(+)-independent neutral amino acid transporter cloned from rat kidney and its expression in mammalian tissues and Xenopus laevis oocytes. (1438248)
1992
46
Somatic cell hybridization of Roberts syndrome and normal lymphoblasts resulting in correction of both the cytogenetic and mutagen hypersensitivity cellular phenotypes. (1763386)
1991
47
Bull-neck, electrocardiographic changes and creatine phosphokinase blood levels in patients with diphtheria. (1845655)
1991
48
Evidence for preserved reading in 'pure alexia'. (2706436)
1989
49
Interaction of adenylosuccinate synthetase with F-actin. (648524)
1978
50
Idiopathic steatorrhea. (13266826)
1955

Variations for Diabetic Polyneuropathy

About this section

Expression for genes affiliated with Diabetic Polyneuropathy

About this section
Search GEO for disease gene expression data for Diabetic Polyneuropathy.

Pathways for genes affiliated with Diabetic Polyneuropathy

About this section

GO Terms for genes affiliated with Diabetic Polyneuropathy

About this section

Biological processes related to Diabetic Polyneuropathy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1mitochondrion organizationGO:00070059.9PARP1, SOD2
2superoxide metabolic processGO:00068019.7SOD2, SOD3
3response to nutrient levelsGO:00316679.7NOS1, SOD2
4transmembrane receptor protein tyrosine kinase signaling pathwayGO:00071699.3NGF, NTF3
5negative regulation of neuron apoptotic processGO:00435248.8NGF, NTF3, SOD2

Sources for Diabetic Polyneuropathy

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet